AXA Framlington has appointed Andy Smith to run its Biotech fund from April.
Smith, who will report to the firm’s CEO, Robert Kyprianou, joins from venture capitalist SV Life Sciences where he managed its International Biotechnology trust. SV has announced David Pinniger, a former Morgan Stanley analyst, will come in to replace Smith. Before joining SV, Smith managed the Bioscience investment trust for five years, initially at 3i and then at Schroders when the trust transferred management house in 2004. In total, his investment career spans 30 years. Kyprianou says: “Andy’s extensive experience in the global pharmaceutical industry and his impressive track reco...
To continue reading this article...
Join Professional Adviser for free
- Unlimited access to real-time news, industry insights and market intelligence
- Stay ahead of the curve with spotlights on emerging trends and technologies
- Receive breaking news stories straight to your inbox in the daily newsletters
- Make smart business decisions with the latest developments in regulation, investing retirement and protection
- Members-only access to the editor’s weekly Friday commentary
- Be the first to hear about our events and awards programmes